1 Lilly also reduced the price of the 2.5 mg and 5 mg vials. These new offerings are ... receiving two years of continuous treatment with Omvoh® (mirikizumab-mrkz) achieved long-term clinical ...

Lilly launches additional Zepbound vial doses and offers new savings for self-pay patients ... end-end-digital-healthcare-experience-through 4. FDA approves Lilly's Omvoh (mirikizumab-mrkz) for ...

Eli Lilly is offering higher-dose vials through its direct-to-consumer website, LillyDirect, which started offering lower doses in vials in August.

These new medicines include Alzheimer's disease treatment Kisunla, ulcerative colitis medication Omvoh, and cancer drug Jaypirca. Of course, Lilly's most important new products are diabetes ...

Eli Lilly is now offering four doses of Zepbound in self-administration vials. The lower-cost self-pay option targets people ...

Eli Lilly (LLY) stock in focus as the company expands Zepbound offerings with new vial formats at discounted prices. Read more here.

Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's disease, extending its use beyond ulcerative colitis (UC) for the first time.